Tumor Immune Microenvironment and the Current Immunotherapy of Cholangiocarcinoma (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2023 Oct 27

PMID 37888583

Authors

Siqi Yang

Ruiqi Zou

Yushi Dai

Yafei Hu

Fuyu Li

Haijie Hu

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy originating from the epithelial system of the bile ducts, and its incidence in recent years is steadily increasing. The immune microenvironment of CCA is characterized by diversity and complexity, with a substantial presence of cancer‑associated fibroblasts and immune cell infiltration, which plays a key role in regulating the distinctive biological behavior of cholangiocarcinoma, including tumor growth, angiogenesis, lymphangiogenesis, invasion and metastasis. Despite the notable success of immunotherapy in the treatment of solid tumors in recent years, patients with CCA have responded poorly to immune checkpoint inhibitor therapy. The interaction of tumor cells with cellular components of the immune microenvironment can regulate the activity and function of immune cells and form an immunosuppressive microenvironment, which may cause ineffective immunotherapy. Therefore, the components of the tumor immune microenvironment appear to be novel targets for immune therapies. Combination therapy focusing on immune checkpoint inhibitors is a promising and valuable first‑line or translational treatment approach for intractable biliary tract malignancies. The present review discusses the compositional characteristics and regulatory factors of the CCA immune microenvironment and the possible immune escape mechanisms. In addition, a summary of the advances in immunotherapy for CCA is also provided. It is hoped that the present review may function as a valuable reference for the development of novel immunotherapeutic strategies for CCA.

Citing Articles

Research hotspots and trends in immunotherapy for cholangiocarcinoma: a bibliometric analysis (2014-2023).

Qu X, Wang Q, Zhu F, Liang H, Long Z, Wu Y Front Immunol. 2024; 15:1436315.

PMID: 39660136 PMC: 11628549. DOI: 10.3389/fimmu.2024.1436315.

Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.

Dadgar N, Arunachalam A, Hong H, Phoon Y, Arpi-Palacios J, Uysal M Cancers (Basel). 2024; 16(18).

PMID: 39335203 PMC: 11429565. DOI: 10.3390/cancers16183232.

Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression.

Chen F, Sheng J, Li X, Gao Z, Hu L, Chen M Front Immunol. 2024; 15:1451474.

PMID: 39290697 PMC: 11405194. DOI: 10.3389/fimmu.2024.1451474.

Prognostic impact of the tumour microenvironment in intrahepatic cholangiocarcinoma: identification of a peritumoural fibro-immune interface.

Lubuela G, Beaufrere A, Albuquerque M, Pignollet C, Nicolle R, Lesurtel M Virchows Arch. 2024; 485(5):901-911.

PMID: 39242455 DOI: 10.1007/s00428-024-03922-5.

Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.

Zhang G, Li J, Li G, Zhang J, Yang Z, Yang L Clin Exp Med. 2024; 24(1):193.

PMID: 39141161 PMC: 11324771. DOI: 10.1007/s10238-024-01460-7.

References

Brandau S, Dumitru C, Lang S . Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2012; 35(2):163-76. DOI: 10.1007/s00281-012-0344-6. View

Oliviero B, Varchetta S, Mele D, Pessino G, Maiello R, Falleni M . MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. Oncoimmunology. 2022; 11(1):2035919. PMC: 8865231. DOI: 10.1080/2162402X.2022.2035919. View

Huang X, Tang T, Zhang G, Liang T . Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021; 20(1):50. PMC: 7938044. DOI: 10.1186/s12943-021-01342-6. View

Bai R, Li Y, Jian L, Yang Y, Zhao L, Wei M . The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol Cancer. 2022; 21(1):177. PMC: 9454207. DOI: 10.1186/s12943-022-01645-2. View

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

Kitano Y, Okabe H, Yamashita Y, Nakagawa S, Saito Y, Umezaki N . Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br J Cancer. 2017; 118(2):171-180. PMC: 5785749. DOI: 10.1038/bjc.2017.401. View

Piha-Paul S, Oh D, Ueno M, Malka D, Chung H, Nagrial A . Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020; 147(8):2190-2198. DOI: 10.1002/ijc.33013. View

Tsukagoshi M, Wada S, Yokobori T, Altan B, Ishii N, Watanabe A . Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma. Cancer Sci. 2015; 107(2):116-22. PMC: 4768394. DOI: 10.1111/cas.12853. View

Panwong S, Wathikthinnakon M, Kaewkod T, Sawasdee N, Tragoolpua Y, Yenchitsomanus P . Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells. Molecules. 2021; 26(19). PMC: 8512070. DOI: 10.3390/molecules26195973. View

10.

Walker N, Crockett P, Nyska A, Brix A, Jokinen M, Sells D . Dose-additive carcinogenicity of a defined mixture of "dioxin-like compounds". Environ Health Perspect. 2005; 113(1):43-8. PMC: 1253708. DOI: 10.1289/ehp.7351. View

11.

Zhang G, Zheng G, Zhang H, Qiu L . MUC1 induces the accumulation of Foxp3 Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway. Int Immunopharmacol. 2023; 118:110091. DOI: 10.1016/j.intimp.2023.110091. View

12.

Lan Y, Zhang D, Xu C, Hance K, Marelli B, Qi J . Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018; 10(424). DOI: 10.1126/scitranslmed.aan5488. View

13.

Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M, Kinoshita M . Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma. Cancer Sci. 2019; 111(2):323-333. PMC: 7004525. DOI: 10.1111/cas.14267. View

14.

Doki Y, Ueno M, Hsu C, Oh D, Park K, Yamamoto N . Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 2022; 11(13):2550-2560. PMC: 9249982. DOI: 10.1002/cam4.4593. View

15.

Mao Z, Zhu G, Xiong M, Ren L, Bai L . Prognostic value of neutrophil distribution in cholangiocarcinoma. World J Gastroenterol. 2015; 21(16):4961-8. PMC: 4408469. DOI: 10.3748/wjg.v21.i16.4961. View

16.

Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q . Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clin Cancer Res. 2017; 24(6):1277-1286. DOI: 10.1158/1078-0432.CCR-17-0432. View

17.

Kim H, Jeong S, Park S, Lee Y, Ju Y, Kim D . Implication of CD69 CD103 tissue-resident-like CD8 T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver Int. 2021; 41(4):764-776. DOI: 10.1111/liv.14814. View

18.

Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C . Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020; 130(10):5380-5396. PMC: 7524481. DOI: 10.1172/JCI137110. View

19.

Liu D, Heij L, Czigany Z, Dahl E, Lang S, Ulmer T . The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin Cancer Res. 2022; 41(1):127. PMC: 8988317. DOI: 10.1186/s13046-022-02340-2. View

20.

Koido S, Kan S, Yoshida K, Yoshizaki S, Takakura K, Namiki Y . Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. Anticancer Res. 2014; 34(11):6353-61. View